Archived Newsletters

81. 07.24.25 -- Investors Create A U.S. Biotech With GLP-1 Assets From China 7/24/2025
    07/24/25 Outsourced Pharma Newsletter
82. 07.23.25 -- The Mighty CDMOs Producing API 7/23/2025
    07/23/25 Outsourced Pharma Newsletter
83. 07.22.25 -- Strategic Considerations For Generic GLP-1 Combination Product Development 7/22/2025

    07/22/25 Outsourced Pharma Newsletter

84. 07.22.25 -- Bioprocess Excellence: Strategies For Speed, Cost, And Quality 7/22/2025

    07/22/25 Outsourced Pharma Newsletter

85. 07.22.25 -- RNAi Vs. mRNA: Two Therapies, Two CDMO Strategies 7/22/2025
    07/22/25 Outsourced Pharma Newsletter
86. 07.21.25 -- The Power Of Collaboration In Uncertain Times 7/21/2025

    07/21/25 Outsourced Pharma Newsletter

87. 07.21.25 -- STREAM Edition: It's Not What You Deserve, It's What You Negotiate 7/21/2025

    07/21/25 Outsourced Pharma Newsletter

88. 07.21.25 -- The Biggest Problem At CDMOs Today 7/21/2025
    07/21/25 Outsourced Pharma Newsletter
89. 07.18.25 -- Why CDMOs Are Leaving Small Molecules Behind 7/18/2025
    07/18/25 Outsourced Pharma Newsletter
90. 07.17.25 -- Innovation driving access in advanced therapies 7/17/2025

    07/17/25 Outsourced Pharma Newsletter